快速生长、中度分化的肝细胞癌：无干扰素直接抗病毒药物治疗后肝细胞癌发生的临床病理特征？ - Suppr

Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?

作者信息

Nakao Yasuhiko, Hashimoto Satoru, Abiru Seigo, Komori Atsumasa, Yamasaki Kazumi, Nagaoka Shinya, Saeki Akira, Bekki Shigemune, Kugiyama Yuki, Kuroki Tamotsu, Ito Masahiro, Nakao Kazuhiko, Yatsuhashi Hiroshi

机构信息

Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.

出版信息

J Hepatol. 2018 Apr;68(4):854-855. doi: 10.1016/j.jhep.2017.11.011. Epub 2017 Nov 13.

DOI:10.1016/j.jhep.2017.11.011

PMID:29146486

Abstract

摘要

相似文献

Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?

J Hepatol. 2018 Apr;68(4):854-855. doi: 10.1016/j.jhep.2017.11.011. Epub 2017 Nov 13.

Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.

PLoS One. 2018 Apr 16;13(4):e0194704. doi: 10.1371/journal.pone.0194704. eCollection 2018.

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.

J Viral Hepat. 2017 Nov;24(11):976-981. doi: 10.1111/jvh.12726. Epub 2017 Aug 3.

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Dig Dis Sci. 2017 Oct;62(10):2932-2942. doi: 10.1007/s10620-017-4739-z. Epub 2017 Sep 7.

Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.

J Hepatol. 2017 Nov;67(5):933-939. doi: 10.1016/j.jhep.2017.05.028. Epub 2017 Jun 14.

Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.

J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.

Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.

J Hepatol. 2016 Oct;65(4):734-740. doi: 10.1016/j.jhep.2016.05.045. Epub 2016 Jun 7.

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19.

Rapidly growing hepatocellular carcinoma recurrence during direct-acting antiviral treatment for chronic hepatitis C.

Clin J Gastroenterol. 2018 Dec;11(6):497-500. doi: 10.1007/s12328-018-0876-y. Epub 2018 Jun 11.

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.

Aliment Pharmacol Ther. 2017 Jan;45(1):160-168. doi: 10.1111/apt.13821. Epub 2016 Oct 28.

引用本文的文献

High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam.

Pharmacol Res Perspect. 2024 Oct;12(5):e70007. doi: 10.1002/prp2.70007.

No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.

Glob Health Med. 2022 Aug 31;4(4):216-224. doi: 10.35772/ghm.2022.01026.

Targeting the effect of sofosbuvir on selective oncogenes expression level of hepatocellular carcinoma Ras/Raf/MEK/ERK pathway in Huh7 cell line.

Saudi J Biol Sci. 2022 Aug;29(8):103332. doi: 10.1016/j.sjbs.2022.103332. Epub 2022 Jun 1.

Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.

PLoS One. 2022 Jan 12;17(1):e0262267. doi: 10.1371/journal.pone.0262267. eCollection 2022.

Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication.

Hepatol Commun. 2021 Sep;5(9):1465-1468. doi: 10.1002/hep4.1733.

Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR.

Cancers (Basel). 2021 Jul 9;13(14):3455. doi: 10.3390/cancers13143455.

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics.

Cancers (Basel). 2020 May 26;12(6):1351. doi: 10.3390/cancers12061351.

Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.

J Med Case Rep. 2020 May 27;14(1):62. doi: 10.1186/s13256-020-02392-y.

Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment.

J Hepatocell Carcinoma. 2020 Apr 15;7:45-76. doi: 10.2147/JHC.S221187. eCollection 2020.

Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals.

Cancers (Basel). 2019 Nov 11;11(11):1773. doi: 10.3390/cancers11111773.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献